Scientists Identify Immune Cell State Behind Long COVID

Researchers at the Helmholtz Centre for Infection Research and the Centre for Individualised Infection Medicine (CiiM) have identified a specific immune cell state that appears to drive the persistent symptoms of Long COVID, a condition that affects an estimated 10 percent of people who contract SARS-CoV-2. The study, published in Nature Immunology in 2026, used single-cell multiomics technology to examine the immune systems of Long COVID patients at unprecedented resolution, revealing a previously uncharacterized cell population that correlates strongly with the fatigue and respiratory symptoms that define the condition. The discovery opens what researchers describe as a direct path toward personalized diagnostic and treatment strategies for a disease that has, until now, resisted clear biological explanation.

The Long COVID Problem

More than four years after the initial waves of the COVID-19 pandemic, Long COVID remains one of the most consequential and least understood legacies of SARS-CoV-2. The condition, formally known as post-acute sequelae of SARS-CoV-2 infection (PASC), encompasses a constellation of symptoms that persist for weeks, months, or years after the acute infection has resolved. These symptoms include debilitating fatigue, cognitive impairment ("brain fog"), shortness of breath, joint and muscle pain, sleep disturbances, and cardiovascular abnormalities, among dozens of others.

The challenge for researchers has been that Long COVID is not a single disease with a single mechanism. Different patients present with different symptom clusters, different severity levels, and different time courses. Some improve gradually over months; others remain symptomatic indefinitely. The underlying biology has been elusive, with multiple hypotheses competing for explanatory primacy: persistent viral reservoirs, autoimmune activation, microbiome disruption, endothelial damage, and immune dysregulation have all been proposed, with evidence supporting each to varying degrees.

What has been missing is a specific cellular or molecular signature that consistently distinguishes Long COVID patients from those who recover fully. Without such a biomarker, diagnosis relies entirely on symptom reporting, treatment is largely supportive rather than targeted, and clinical trials struggle to identify the patients most likely to benefit from experimental interventions. The Helmholtz/CiiM study addresses this gap directly.

The Discovery: LC-Mo Cells

The research team, led by Professor Yang Li, applied single-cell multiomics, a set of techniques that simultaneously measure gene expression, protein levels, and chromatin accessibility in individual cells, to blood samples from Long COVID patients and matched controls who had recovered fully from COVID-19.

What they found was a distinct population of CD14+ monocytes (a type of white blood cell involved in immune defense and inflammation) that existed in a previously uncharacterized activation state. The team designated this population "LC-Mo" (Long COVID Monocytes). These cells were not a new type of immune cell but rather an existing cell type (CD14+ monocytes) that had been pushed into an abnormal functional state, producing elevated levels of inflammatory signaling molecules (cytokines) and displaying altered gene expression patterns that distinguished them clearly from normal monocytes in recovered patients.

Think of monocytes as patrol officers in the immune system's police force. Normally, they circulate through the blood, monitoring for signs of infection or tissue damage. When they detect a threat, they activate, producing inflammatory signals that recruit other immune cells to the scene. In Long COVID patients, the LC-Mo population behaves as though it is permanently on high alert, producing inflammatory signals even in the absence of an active infection. It is as if a group of patrol officers received an alarm call that was never canceled: they remain in emergency mode indefinitely, disrupting normal operations in the neighborhoods they patrol.

The clinical significance of this finding was strengthened by the correlation with specific symptoms. LC-Mo levels were most elevated in patients reporting fatigue and respiratory symptoms, two of the most common and debilitating features of Long COVID. This correlation suggests that the inflammatory activity of LC-Mo cells may directly contribute to these symptoms, potentially by sustaining low-grade inflammation in tissues such as the lungs and muscles.

Single-Cell Multiomics: Seeing What Was Hidden

The identification of LC-Mo cells was made possible by technological advances that were not available during the early stages of the pandemic. Traditional immune profiling techniques, such as flow cytometry and bulk RNA sequencing, measure average properties across large populations of cells. They can identify broad changes (more monocytes overall, higher average cytokine levels) but cannot resolve differences between individual cells within a population.

Single-cell multiomics changes this. By analyzing thousands of individual cells simultaneously, the technique can identify rare or subtle subpopulations that would be invisible to bulk methods. In the case of LC-Mo cells, the abnormal monocyte population was present alongside normal monocytes in the same patients. A bulk analysis would average their signals together, potentially obscuring the LC-Mo signature entirely. Only by examining cells one at a time could the researchers distinguish the pathological population from the healthy background.

The "multi" in multiomics refers to the fact that the technique measures multiple types of molecular information simultaneously. For each cell, the researchers could see:

Transcriptomics: Which genes are being actively expressed (turned into RNA), revealing the cell's current functional program.
Proteomics: Which proteins are present on the cell surface or inside it, providing information about the cell's identity and activation state.
Epigenomics: The accessibility of different regions of the cell's DNA (chromatin state), which indicates not just what the cell is doing now but what it is primed to do in the future.

This multi-layered view is what allowed the team to characterize LC-Mo cells with such specificity. The cells showed a unique combination of gene expression changes, surface protein alterations, and chromatin accessibility patterns that collectively define a distinct cellular state, one not previously catalogued in the immunology literature. The technological approach parallels the multi-instrument strategies used in planetary science research combining data from multiple spacecraft.

The Cytokine Connection

One of the most actionable findings from the study is the identification of specific cytokines (inflammatory signaling proteins) that are elevated in LC-Mo cells. Cytokines are the immune system's communication network: they coordinate the response to infection, direct immune cells to areas of damage, regulate inflammation, and, when dysregulated, can cause significant tissue harm.

The specific cytokines overproduced by LC-Mo cells include several that have been independently implicated in Long COVID through other research approaches, providing convergent evidence that the LC-Mo population is mechanistically relevant rather than merely correlated. While the full cytokine profile is complex, the elevated molecules include pro-inflammatory mediators known to contribute to fatigue, muscle pain, and respiratory inflammation when present at chronically elevated levels.

This cytokine signature has direct therapeutic implications. Several existing drugs target specific cytokines or the signaling pathways they activate. If the LC-Mo cytokine profile can be validated in larger patient cohorts, it could guide the selection of targeted anti-inflammatory therapies for Long COVID patients, replacing the current approach of broadly supportive care with precision interventions aimed at the specific inflammatory pathways that are driving symptoms.

Professor Yang Li described the therapeutic potential:

"By identifying the specific immune cell population and the inflammatory mediators it produces, we have moved from treating Long COVID as a syndrome of unknown cause to understanding it as a condition with a definable biological mechanism. This opens the door to personalized treatment strategies based on each patient's immune profile."
Professor Yang Li, Helmholtz Centre for Infection Research / CiiM

Why Mild and Moderate Cases Are Affected

One of the more counterintuitive aspects of Long COVID is that it frequently develops after mild or moderate acute infections, not just severe ones. Patients who were never hospitalized, who experienced COVID-19 as a bad cold or a brief flu-like illness, can develop persistent symptoms that last months or years. This pattern has been difficult to explain: if Long COVID were simply a consequence of severe tissue damage from the acute infection, it should be most common in the sickest patients.

The LC-Mo finding offers a potential explanation. The study found that LC-Mo cells were most prevalent after mild and moderate COVID-19, not after severe disease. This suggests that the immune dysregulation driving Long COVID may be triggered by a specific pattern of immune activation that is more characteristic of milder infections, possibly one in which the immune response is sufficient to clear the virus but does so in a way that leaves certain monocyte populations in a persistently altered state.

One hypothesis consistent with this finding is that severe COVID-19, which involves massive immune activation and often intensive medical intervention (including corticosteroids and other immunomodulatory drugs), may paradoxically reset the immune system more completely during recovery. Mild infections, which do not trigger the same level of immune activation or receive the same therapeutic interventions, may leave residual immune perturbations that persist. This is speculative, but the pattern observed in the data is suggestive and warrants further investigation.

The clinical implication is important: Long COVID screening and monitoring should not be limited to patients who experienced severe acute disease. The findings suggest that patients with mild infections may actually be at higher risk for developing the specific immune dysregulation identified in this study.

Toward Personalized Treatment

The identification of LC-Mo cells and their associated cytokine profile provides a foundation for several practical advances in Long COVID management:

Diagnostic biomarker: If the LC-Mo cell population can be reliably detected through standard blood tests (perhaps using a panel of surface markers identified in the multiomics analysis), it could serve as an objective diagnostic test for Long COVID, replacing the current reliance on subjective symptom reporting.
Patient stratification: Not all Long COVID patients may have elevated LC-Mo cells. The study's correlation with specific symptom clusters (fatigue and respiratory symptoms) suggests that LC-Mo-driven disease may represent a distinct subtype of Long COVID. Identifying this subtype could allow clinical trials to enroll more homogeneous patient populations, increasing the likelihood of detecting treatment effects.
Targeted therapy: Anti-inflammatory drugs that target the specific cytokines or signaling pathways activated in LC-Mo cells could be tested in clinical trials. Because these drugs already exist (many were developed for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease), the path from identification to clinical testing is shorter than it would be for an entirely new drug.
Monitoring: LC-Mo levels could be tracked over time to assess whether a patient is improving, worsening, or responding to treatment, providing an objective measure of disease activity that is currently lacking. This type of precision monitoring parallels the approach used by researchers developing targeted molecular technologies in other fields.

Limitations and Next Steps

The study, while significant, has several important limitations that the authors and independent commentators have noted.

First, the sample size, though sufficient for the single-cell multiomics analysis, was relatively modest. Larger validation studies across diverse patient populations will be needed to confirm that the LC-Mo signature is reproducible and generalizable. Immune responses vary with age, sex, ethnicity, vaccination status, and the specific SARS-CoV-2 variant responsible for infection, and all of these variables will need to be accounted for.

Second, correlation is not causation. The study shows that LC-Mo cells are present in Long COVID patients and correlate with specific symptoms, but it does not definitively prove that they cause those symptoms. It is possible that LC-Mo cells are a consequence rather than a driver of the underlying disease process, or that they are one contributing factor among several. Experimental studies, potentially including clinical trials of therapies that specifically target LC-Mo cells, will be needed to establish the causal relationship.

Third, the study focused on blood-circulating monocytes. Long COVID affects many organ systems, and the relevant immune pathology may be occurring primarily in tissues (lungs, brain, gut) rather than in the bloodstream. The LC-Mo population detected in blood may represent only a fraction of the dysregulated immune cells in the body, or it may reflect a tissue-level process that is partially mirrored in the circulation. Tissue biopsy studies, while more invasive and difficult to conduct, would provide a more complete picture.

Despite these caveats, the identification of LC-Mo cells represents one of the most concrete biological findings in Long COVID research to date. It provides a specific target for further investigation, a potential diagnostic marker, and a rational basis for therapeutic intervention. For the millions of people worldwide living with Long COVID, that specificity is meaningful. It transforms the conversation from "something is wrong with your immune system" to "we can identify what is wrong and we have ideas about how to fix it." That shift, from vague to precise, from supportive to targeted, is where effective treatments begin. Discoveries like this reinforce why understanding immune responses at the cellular level, whether in human disease or in biological research more broadly, demands the most advanced analytical tools available.